Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Published byThea Tordis Ludvigsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,"— Presentation transcript:

1 Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation 
Kris De Boeck, Anne Munck, Seth Walker, Albert Faro, Peter Hiatt, Geoffrey Gilmartin, Mark Higgins  Journal of Cystic Fibrosis  Volume 13, Issue 6, Pages (December 2014) DOI: /j.jcf Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

2 Fig. 1 Mean absolute change from baseline after 8weeks of treatment in (A) percent predicted FEV1; (B) BMI; (C) sweat chloride; and (D) CFQ-R respiratory domain score. BMI=body mass index; CFQ-R=Cystic Fibrosis Questionnaire-Revised. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

3 Fig. 2 Mean absolute change from baseline in percent predicted FEV1 over 24weeks of ivacaftor treatment for patients from treatment sequence 2 (placebo→ivacaftor). Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Download ppt "Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,"

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan 

Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation  Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation  Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,
Treatment compliance in children and adults with Cystic Fibrosis

Treatment compliance in children and adults with Cystic Fibrosis
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation  Gemma L. Zeybel, Jeffrey P. Pearson, Amaran Krishnan,

Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation  Gemma L. Zeybel, Jeffrey P. Pearson, Amaran Krishnan,
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings  Gwen Duytschaever, Geert Huys,

Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings  Gwen Duytschaever, Geert Huys,
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.

Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 

Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.
John Widger, Sarath Ranganathan, Philip J. Robinson 

John Widger, Sarath Ranganathan, Philip J. Robinson 
The ease of breathing test tracks clinical changes in cystic fibrosis

The ease of breathing test tracks clinical changes in cystic fibrosis
Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis  Antoine Regnault, Maria-Magdalena Balp, Károly.

Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis  Antoine Regnault, Maria-Magdalena Balp, Károly.
Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation  Shahid I. Sheikh, Frederick R. Long, Karen.

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation  Shahid I. Sheikh, Frederick R. Long, Karen.
Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection  Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection  Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,
Controlled clinical trials in cystic fibrosis — are we doing better?

Controlled clinical trials in cystic fibrosis — are we doing better?
Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease  Peter Witters, Kris De Boeck, Lieven Dupont, Marijke.

Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease  Peter Witters, Kris De Boeck, Lieven Dupont, Marijke.

Similar presentations

Ads by Google